EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.14.5 | medicine | inhibition of DPP-IV can be an effective approach to treat type 2 diabetes mellitus by potentiating insulin secretion. 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, i.e. KR-62436, could be good lead compound for further development as a new anti-diabetic agent | Homo sapiens |
3.4.14.5 | medicine | inhibition of DPP-IV can be an effective approach to treat type 2 diabetes mellitus by potentiating insulin secretion. 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, i.e. KR-62436, could be good lead compound for further development as a new anti-diabetic agent | Rattus norvegicus |
3.4.14.5 | medicine | inhibition of DPP-IV can be an effective approach to treat type 2 diabetes mellitus by potentiating insulin secretion. 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, i.e. KR-62436, could be good lead compound for further development as a new anti-diabetic agent | Sus scrofa |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.14.5 | 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile | i.e. KR-62436, IC50: 0.00014 mM, selective competitive inhibitor, good lead compound for further development as a new anti-diabetic agent, almost completely inhibits DPP-IV mediated degradation of glucagon-like peptide-1 | Homo sapiens | |
3.4.14.5 | 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile | i.e. KR-62436, IC50: 0.00078 mM, selective competitive inhibitor, good lead compound for further development as a new anti-diabetic agent, almost completely inhibits DPP-IV mediated degradation of glucagon-like peptide-1 | Rattus norvegicus | |
3.4.14.5 | 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile | i.e. KR-62436, IC50: 0.00049 mM, selective competitive inhibitor, good lead compound for further development as a new anti-diabetic agent, almost completely inhibits DPP-IV mediated degradation of glucagon-like peptide-1 | Sus scrofa |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.14.5 | Homo sapiens | - |
- |
- |
3.4.14.5 | Rattus norvegicus | - |
- |
- |
3.4.14.5 | Sus scrofa | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.14.5 | blood plasma | - |
Rattus norvegicus | - |
3.4.14.5 | kidney | - |
Sus scrofa | - |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.14.5 | DPP-IV | - |
Homo sapiens |
3.4.14.5 | DPP-IV | - |
Rattus norvegicus |
3.4.14.5 | DPP-IV | - |
Sus scrofa |
EC Number | IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|---|
3.4.14.5 | 0.00014 | - |
i.e. KR-62436, IC50: 0.00014 mM, selective competitive inhibitor, good lead compound for further development as a new anti-diabetic agent, almost completely inhibits DPP-IV mediated degradation of glucagon-like peptide-1 | Homo sapiens | 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile | |
3.4.14.5 | 0.00049 | - |
i.e. KR-62436, IC50: 0.00049 mM, selective competitive inhibitor, good lead compound for further development as a new anti-diabetic agent, almost completely inhibits DPP-IV mediated degradation of glucagon-like peptide-1 | Sus scrofa | 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile | |
3.4.14.5 | 0.00078 | - |
i.e. KR-62436, IC50: 0.00078 mM, selective competitive inhibitor, good lead compound for further development as a new anti-diabetic agent, almost completely inhibits DPP-IV mediated degradation of glucagon-like peptide-1 | Rattus norvegicus | 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile |